K12/A322+His_pET-28a(+)
(Plasmid
#255042)
-
PurposeRecombinant tau construct for seeding activity assays and other applications.
-
Depositing Lab
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 255042 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
Backbone
-
Vector backbonepET-28a(+)
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert namemodified tau protein (K12)
-
SpeciesH. sapiens (human)
-
MutationThe K12 tau fragment (residues 244-275 and 306-400 of the full-length human tau sequence) with an alanine mutation at residue 322.
-
Entrez GeneMAPT (a.k.a. DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU, Tau-PHF6, tau-40)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site Unknown (unknown if destroyed)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
A cloning cassette encoding the K12 tau fragment (residues 244-275 and 306-400 of the full-length human tau sequence) with an alanine mutation at residue 322, thereby rendering it cysteine-free (K12CF), was introduced between the Ndel and XhoI sites of the pET28 bacterial vector resulting in a histidine tag at the N-terminal (K12CFh). The cysteine was mutated in order to prevent disulfide-mediated dimerization of the K12 molecules.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
K12/A322+His_pET-28a(+) was a gift from Byron Caughey (Addgene plasmid # 255042 ; http://n2t.net/addgene:255042 ; RRID:Addgene_255042) -
For your References section:
Classification of tauopathies from human brain homogenates through salt-modulated tau amplification. Santambrogio A, Metrick MA 2nd, Xu P, Gallagher NCT, Koga S, Ghetti B, Dickson DW, Caughey B, Vendruscolo M. Alzheimers Dement. 2026 Feb;22(2):e71112. doi: 10.1002/alz.71112. 10.1002/alz.71112 PubMed 41685551